Highlights OncoCyte Corporation

Equities

OCX

US68235C2061

Delayed Nasdaq Other stock markets 10:01:08 2024-05-07 am EDT			5-day change	1st Jan Change
2.825 ^USD	+1.99%		+13.45%	+13.00%

Apr. 25	OncoCyte Corporation announced that it has received $15.807655 million in funding	CI
Apr. 16	Broadwood Capital, Inc. Engages with OncoCyte Corporation	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 12	MT
OncoCyte Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay	Apr. 11	CI
Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays	Dec. 06	CI
OncoCyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
OncoCyte Says VitaGraft Kidney Diagnostic Test to Receive Medicare, Medicaid Coverage	23-08-28	MT
Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage	23-08-28	CI
Earnings Flash (OCX) ONCOCYTE CORPORATION Reports Q2 Revenue $463,000, vs. Street Est of $0.35M	23-08-10	MT
OncoCyte Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients	23-07-25	CI
Earnings Flash (OCX) ONCOCYTE CORPORATION Posts Q1 Revenue $297,000, vs. Street Est of $340,000	23-05-11	MT
OncoCyte Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Oncocyte Corporation Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer	23-04-07	CI
Earnings Flash (OCX) ONCOCYTE CORPORATION Posts Q4 Revenue $958,000, vs. Street Est of $1.42M	23-03-31	MT
OncoCyte Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Dragon Scientific, LLC acquired 70% stake in Razor Genomics Inc. from OncoCyte Corporation.	23-02-15	CI
Dragon Scientific, LLC entered into a Stock Purchase Agreement to acquire 70% stake in Razor Genomics Inc. from OncoCyte Corporation.	22-12-15	CI
OncoCyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Earnings Flash (OCX) ONCOCYTE CORPORATION Reports Q3 Revenue $1M	22-11-10	MT
OncoCyte Corporation Announces DetermaIO(TM) Clinical Test to Use in SWOG Cancer Research Network Biomarker Study for Breast Cancer	22-10-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OncoCyte Corporation

Equities

OCX

US68235C2061

Highlights

Filters